Insulin Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Pages: 318 Published: September 19, 2022 Report Code: GDME1437EPD

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    https://www.ispeech.org/text.to.speech

Insulin delivery devices are used to inject measured doses of insulin through the skin and into the fatty tissues below. The Insulin Delivery pipeline market research report provides comprehensive information about the Insulin Delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Territory Outlook of the Insulin Delivery Pipeline Products Market

Some of the key territories with products in the pipeline are the US, Europe, China, Israel, South Korea, Canada, Australia, India, the UAE, and Hong Kong. As of September 2022, the US has the highest number of products in the pipeline out of them all.

Insulin Delivery Pipeline Products Market Analysis, by Territories

Insulin Delivery Pipeline Products Market Analysis, by Territories

For more territory insights into the Insulin delivery pipeline products market, download a free report sample

Insulin Delivery Pipeline Products Market by Key Segments

Some of the key segments in the Insulin delivery pipeline products market are Insulin Pumps, Patch Pumps, Insulin Pens, Reusable Insulin Pens, Disposable Insulin Pens, Disposable Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, and Programmable Insulin Patch Pumps – Pods.

Insulin Delivery Pipeline Products Market Analysis, by Segments

Insulin Delivery Pipeline Products Market Analysis, by Segments

For more segment insights into the Insulin delivery pipeline products market, download a free report sample

Insulin Delivery Pipeline Products Market Segmentation by Key Regulatory Paths

The key regulatory paths followed by the Insulin delivery pipeline products market 510(k), CE, NMPA, PMA, MDITAC, MDL, TGA, ICAC, MDCO, and Ninsho. Most of the products follow the 510(k) pathway to enter the market.

Insulin Delivery Pipeline Products Market Analysis, by Regulatory Paths

Insulin Delivery Pipeline Products Market Analysis, by Regulatory Paths

For more regulatory path insights into the Insulin delivery pipeline, download a free report sample

Competitive Landscape

Some of the key companies in the Insulin delivery pipeline products market are Abbott Diabetes Care Inc, Aerami Therapeutics Inc, American Chemical Society, AMF Medical SA, Amrita Vishwa Vidyapeetham, Andain, Inc, Animas Corp, ASTI Corp, Avecho Biotechnology Ltd, and Becton Dickinson and Co.

Abbott Diabetes Care Inc: It is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitoring systems, diagnostics, medical devices, nutritionals, generic pharmaceuticals, and diabetes products. The company has a presence in the US, the Americas, Africa, Asia Pacific, and the Middle East. ADC is headquartered in Alameda, California, the US.

Aerami Therapeutics Inc: It is a biotechnology company that develops inhaled insulin products to treat diabetes patients. The company develops liquid formulation of insulin based on the vibrating mesh micropump technology developed and commercialized by Aerogen. Aerami is headquartered in San Francisco, California, the US.

American Chemical Society: It is a non-profit organization that provides various scientific information through its peer-reviewed scientific journals and national conferences and is also engaged in chemical abstracts-related services. It also publishes chemical and engineering news related magazines for its users. The company is headquartered in Washington, the US.

Insulin Delivery Pipeline Products Market Report Overview

Key Territories The US, Europe, China, Israel, South Korea, Canada, Australia, India, the UAE, and Hong Kong
Key Segments Insulin Pumps, Patch Pumps, Insulin Pens, Reusable Insulin Pens, Disposable Insulin Pens, Disposable Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, and Programmable Insulin Patch Pumps – Pods
Key Regulatory Paths 510(k), CE, NMPA, PMA, MDITAC, MDL, TGA, ICAC, MDCO, and Ninsho
Key Companies Abbott Diabetes Care Inc, Aerami Therapeutics Inc, American Chemical Society, AMF Medical SA, Amrita Vishwa Vidyapeetham, Andain, Inc, Animas Corp, ASTI Corp, Avecho Biotechnology Ltd, and Becton Dickinson and Co

Scope

This report provides:

  • Extensive coverage of the Insulin Delivery under development.
  • Details of major pipeline products which include product description, licensing, collaboration details, and other developmental activities.
  • Reviews of the major players involved in the development of Insulin Delivery and lists all their pipeline projects.
  • The coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Identify and understand important and diverse types of Insulin Delivery under development.
  • Develop market-entry and market expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Key Players

Abbott Diabetes Care Inc

Aerami Therapeutics Inc

American Chemical Society

AMF Medical SA

Amrita Vishwa Vidyapeetham

Andain, Inc

Animas Corp

ASTI Corp

Avecho Biotechnology Ltd

Becton Dickinson and Co

Bigfoot Biomedical Inc

Biocon Ltd

Cambridge Consultants Ltd

Cellnovo Ltd (Inactive)

Companion Medical Inc

ConvaTec Group Plc

Debiotech SA

Defymed SAS

Dermisonics Inc

Eli Lilly and Co

Emperra GmbH E-Health Technologies

EOFlow Co Ltd

Erech Finance Cahalacha Ltd

Hospira Inc

Imagine Medical Device Inc.

InsuLenz

Insulet Corp

Iowa State University

Kailian Medical Technology Co Ltd

LifeScan Inc

MannKind Corp

Medical International Technologies (Mit Canada) Inc

Medicsensors SL

MedPro Safety Products, Inc.

MedSolve Technologies, Inc.

Medtronic MiniMed Inc

Medtronic Plc

MicroPort Scientific Corp

MicroTech Medical Co Ltd

Modular Medical Inc

NanoDerma Ltd

nGageIT Digital Health Inc

Nitto Denko Corp

North Carolina State University

Novo Nordisk AS

NuGen Medical Devices Inc

Pennsylvania State University

Perikinetics Inc

Phluid Corporation

PhysioLogic Devices Inc

PositiveID Corp

Prometheon Pharma LLC

Qlibrium Inc

Sanofi

SFC Fluidics LLC

Sooil Development Co., Ltd.

Spring Health Solutions Ltd.

Tandem Diabetes Care Inc

TempraMed Israel Ltd

Thermalin Inc

Transdermal Specialties Inc

Triple Jump Israel Ltd

University of KwaZulu-Natal

University of Limerick

University of Massachusetts Amherst

University of Missouri-Kansas City

University of North Carolina

University of Toronto

Univlabs Technologies Pvt Ltd

Unomedical a/s

Valeritas Inc

ViCentra BV

Vigmed Holding AB

Washington University School of Medicine

Ypsomed Holding AG

Zealand Pharma AS

Zenomics Inc

Table of Contents

1 Table of Contents 3

|1.1 List of Tables 11

|1.2 List of Figures 19

2 Introduction 20

2.1 Insulin Delivery Overview 20

3 Products under Development 21

3.1 Insulin Delivery – Pipeline Products by Stage of Development 21

3.2 Insulin Delivery – Pipeline Products by Segment 22

3.3 Insulin Delivery – Pipeline Products by Territory 23

3.4 Insulin Delivery – Pipeline Products by Regulatory Path 24

3.5 Insulin Delivery – Pipeline Products by Estimated Approval Date 25

3.6 Insulin Delivery – Ongoing Clinical Trials 26

4 Insulin Delivery – Pipeline Products under Development by Companies 27

4.1 Insulin Delivery Companies – Pipeline Products by Stage of Development 27

4.2 Insulin Delivery – Pipeline Products by Stage of Development 30

5 Insulin Delivery Companies and Product Overview 33

5.1 Abbott Diabetes Care Inc Company Overview 33

5.1.1 Abbott Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview 33

5.2 Aerami Therapeutics Inc Company Overview 34

5.2.1 Aerami Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

5.3 American Chemical Society Company Overview 35

5.3.1 American Chemical Society Pipeline Products & Ongoing Clinical Trials Overview 35

5.4 AMF Medical SA Company Overview 36

5.4.1 AMF Medical SA Pipeline Products & Ongoing Clinical Trials Overview 36

5.5 Amrita Vishwa Vidyapeetham Company Overview 37

5.5.1 Amrita Vishwa Vidyapeetham Pipeline Products & Ongoing Clinical Trials Overview 37

5.6 Andain, Inc Company Overview 38

5.6.1 Andain, Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.7 Animas Corp Company Overview 40

5.7.1 Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 40

5.8 ASTI Corp Company Overview 41

5.8.1 ASTI Corp Pipeline Products & Ongoing Clinical Trials Overview 41

5.9 Avecho Biotechnology Ltd Company Overview 42

5.9.1 Avecho Biotechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview 42

5.10 Becton Dickinson and Co Company Overview 43

5.10.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 43

5.11 Bigfoot Biomedical Inc Company Overview 45

5.11.1 Bigfoot Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 45

5.12 Biocon Ltd Company Overview 46

5.12.1 Biocon Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

5.13 Cambridge Consultants Ltd Company Overview 47

5.13.1 Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 47

5.14 Cellnovo Ltd (Inactive) Company Overview 48

5.14.1 Cellnovo Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 48

5.15 Companion Medical Inc Company Overview 49

5.15.1 Companion Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 49

5.16 ConvaTec Group Plc Company Overview 50

5.16.1 ConvaTec Group Plc Pipeline Products & Ongoing Clinical Trials Overview 50

5.17 Debiotech SA Company Overview 51

5.17.1 Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 51

5.18 Defymed SAS Company Overview 53

5.18.1 Defymed SAS Pipeline Products & Ongoing Clinical Trials Overview 53

5.19 Dermisonics Inc Company Overview 56

5.19.1 Dermisonics Inc Pipeline Products & Ongoing Clinical Trials Overview 56

5.20 Eli Lilly and Co Company Overview 57

5.20.1 Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview 57

5.21 Emperra GmbH E-Health Technologies Company Overview 61

5.21.1 Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 61

5.22 EOFlow Co Ltd Company Overview 62

5.22.1 EOFlow Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

5.23 Erech Finance Cahalacha Ltd Company Overview 64

5.23.1 Erech Finance Cahalacha Ltd Pipeline Products & Ongoing Clinical Trials Overview 64

5.24 Hospira Inc Company Overview 65

5.24.1 Hospira Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.25 Imagine Medical Device Inc. Company Overview 66

5.25.1 Imagine Medical Device Inc. Pipeline Products & Ongoing Clinical Trials Overview 66

5.26 InsuLenz Company Overview 67

5.26.1 InsuLenz Pipeline Products & Ongoing Clinical Trials Overview 67

5.27 Insulet Corp Company Overview 68

5.27.1 Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 68

5.28 Iowa State University Company Overview 76

5.28.1 Iowa State University Pipeline Products & Ongoing Clinical Trials Overview 76

5.29 Kailian Medical Technology Co Ltd Company Overview 77

5.29.1 Kailian Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 77

5.30 LifeScan Inc Company Overview 80

5.30.1 LifeScan Inc Pipeline Products & Ongoing Clinical Trials Overview 80

5.31 MannKind Corp Company Overview 81

5.31.1 MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview 81

5.32 Medical International Technologies (Mit Canada) Inc Company Overview 83

5.32.1 Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 83

5.33 Medicsensors SL Company Overview 84

5.33.1 Medicsensors SL Pipeline Products & Ongoing Clinical Trials Overview 84

5.34 MedPro Safety Products, Inc. Company Overview 85

5.34.1 MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 85

5.35 MedSolve Technologies, Inc. Company Overview 86

5.35.1 MedSolve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 86

5.36 Medtronic MiniMed Inc Company Overview 87

5.36.1 Medtronic MiniMed Inc Pipeline Products & Ongoing Clinical Trials Overview 87

5.37 Medtronic Plc Company Overview 99

5.37.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 99

5.38 MicroPort Scientific Corp Company Overview 100

5.38.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 100

5.39 MicroTech Medical Co Ltd Company Overview 102

5.39.1 MicroTech Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 102

5.40 Modular Medical Inc Company Overview 104

5.40.1 Modular Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 104

5.41 NanoDerma Ltd Company Overview 106

5.41.1 NanoDerma Ltd Pipeline Products & Ongoing Clinical Trials Overview 106

5.42 nGageIT Digital Health Inc Company Overview 107

5.42.1 nGageIT Digital Health Inc Pipeline Products & Ongoing Clinical Trials Overview 107

5.43 Nitto Denko Corp Company Overview 108

5.43.1 Nitto Denko Corp Pipeline Products & Ongoing Clinical Trials Overview 108

5.44 North Carolina State University Company Overview 110

5.44.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 110

5.45 Novo Nordisk AS Company Overview 111

5.45.1 Novo Nordisk AS Pipeline Products & Ongoing Clinical Trials Overview 111

5.46 NuGen Medical Devices Inc Company Overview 114

5.46.1 NuGen Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 114

5.47 Pennsylvania State University Company Overview 115

5.47.1 Pennsylvania State University Pipeline Products & Ongoing Clinical Trials Overview 115

5.48 Perikinetics Inc Company Overview 116

5.48.1 Perikinetics Inc Pipeline Products & Ongoing Clinical Trials Overview 116

5.49 Phluid Corporation Company Overview 117

5.49.1 Phluid Corporation Pipeline Products & Ongoing Clinical Trials Overview 117

5.50 PhysioLogic Devices Inc Company Overview 118

5.50.1 PhysioLogic Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 118

5.51 PositiveID Corp Company Overview 119

5.51.1 PositiveID Corp Pipeline Products & Ongoing Clinical Trials Overview 119

5.52 Prometheon Pharma LLC Company Overview 120

5.52.1 Prometheon Pharma LLC Pipeline Products & Ongoing Clinical Trials Overview 120

5.53 Qlibrium Inc Company Overview 122

5.53.1 Qlibrium Inc Pipeline Products & Ongoing Clinical Trials Overview 122

5.54 Sanofi Company Overview 123

5.54.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 123

5.55 SFC Fluidics LLC Company Overview 124

5.55.1 SFC Fluidics LLC Pipeline Products & Ongoing Clinical Trials Overview 124

5.56 Sooil Development Co., Ltd. Company Overview 127

5.56.1 Sooil Development Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 127

5.57 Spring Health Solutions Ltd. Company Overview 128

5.57.1 Spring Health Solutions Ltd. Pipeline Products & Ongoing Clinical Trials Overview 128

5.58 Tandem Diabetes Care Inc Company Overview 129

5.58.1 Tandem Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview 129

5.59 TempraMed Israel Ltd Company Overview 137

5.59.1 TempraMed Israel Ltd Pipeline Products & Ongoing Clinical Trials Overview 137

5.60 Thermalin Inc Company Overview 138

5.60.1 Thermalin Inc Pipeline Products & Ongoing Clinical Trials Overview 138

5.61 Transdermal Specialties Inc Company Overview 141

5.61.1 Transdermal Specialties Inc Pipeline Products & Ongoing Clinical Trials Overview 141

5.62 Triple Jump Israel Ltd Company Overview 142

5.62.1 Triple Jump Israel Ltd Pipeline Products & Ongoing Clinical Trials Overview 142

5.63 University of KwaZulu-Natal Company Overview 143

5.63.1 University of KwaZulu-Natal Pipeline Products & Ongoing Clinical Trials Overview 143

5.64 University of Limerick Company Overview 144

5.64.1 University of Limerick Pipeline Products & Ongoing Clinical Trials Overview 144

5.65 University of Massachusetts Amherst Company Overview 145

5.65.1 University of Massachusetts Amherst Pipeline Products & Ongoing Clinical Trials Overview 145

5.66 University of Missouri-Kansas City Company Overview 146

5.66.1 University of Missouri-Kansas City Pipeline Products & Ongoing Clinical Trials Overview 146

5.67 University of North Carolina Company Overview 147

5.67.1 University of North Carolina Pipeline Products & Ongoing Clinical Trials Overview 147

5.68 University of Toronto Company Overview 149

5.68.1 University of Toronto Pipeline Products & Ongoing Clinical Trials Overview 149

5.69 Univlabs Technologies Pvt Ltd Company Overview 150

5.69.1 Univlabs Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 150

5.70 Unomedical a/s Company Overview 151

5.70.1 Unomedical a/s Pipeline Products & Ongoing Clinical Trials Overview 151

5.71 Valeritas Inc Company Overview 152

5.71.1 Valeritas Inc Pipeline Products & Ongoing Clinical Trials Overview 152

5.72 ViCentra BV Company Overview 154

5.72.1 ViCentra BV Pipeline Products & Ongoing Clinical Trials Overview 154

5.73 Vigmed Holding AB Company Overview 156

5.73.1 Vigmed Holding AB Pipeline Products & Ongoing Clinical Trials Overview 156

5.74 Washington University School of Medicine Company Overview 157

5.74.1 Washington University School of Medicine Pipeline Products & Ongoing Clinical Trials Overview 157

5.75 Ypsomed Holding AG Company Overview 158

5.75.1 Ypsomed Holding AG Pipeline Products & Ongoing Clinical Trials Overview 158

5.76 Zealand Pharma AS Company Overview 164

5.76.1 Zealand Pharma AS Pipeline Products & Ongoing Clinical Trials Overview 164

5.77 Zenomics Inc Company Overview 169

5.77.1 Zenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 169

6 Insulin Delivery- Recent Developments 170

6.1 Sep 08, 2022: Robert G. Riney Named Henry Ford Health President and CEO 170

6.2 Sep 07, 2022: Medtronic to appear at September investor conferences 170

6.3 Sep 06, 2022: LifeScan Names Rekha Ramesh Chief Digital and Information Officer 170

6.4 Sep 06, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 171

6.5 Sep 05, 2022: Sanofi announce Evolution of the Board of Directors 171

6.6 Sep 01, 2022: Bayer Announces Appointment of Kimberly Mathisen to Supervisory Board 172

6.7 Aug 31, 2022: Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference 172

6.8 Aug 31, 2022: Pfizer lures first chief marketing officer from Verily 172

6.9 Aug 25, 2022: Lilly to Participate in Citi’s 17th Annual BioPharma Conference 173

6.10 Aug 24, 2022: Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company 173

6.11 Aug 24, 2022: BD to Present at the Wells Fargo 2022 Healthcare Conference 173

6.12 Aug 24, 2022: JNJ Appoints Merlo as Non-Executive Chair Designate 174

6.13 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results 174

6.14 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results 176

6.15 Aug 22, 2022: Tandem Diabetes Care Announces Upcoming Conference Presentations 179

6.16 Aug 20, 2022: Herbert Smith Freehills advises Sanofi on €300 million equity investment in Innovent 179

6.17 Aug 19, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 180

6.18 Aug 18, 2022: embecta to Participate in Upcoming Investor Conferences in September 180

6.19 Aug 17, 2022: Cambridge Cognition selected by the University of Oxford as a cognitive assessment partner for the ISAP study 180

6.20 Aug 15, 2022: Retractable Technologies Announces Results for the Periods Ended June 30, 2022 181

6.21 Aug 09, 2022: Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference 182

6.22 Aug 02, 2022: Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference 182

6.23 Jul 29, 2022: AstraZeneca announce Michel Demaré to succeed Leif Johansson as Non-Executive Chair of the Board 183

6.24 Jul 28, 2022: Sanofi’s half-year financial report for 2022 183

6.25 Jul 28, 2022: Integer Holdings Reports Second Quarter 2022 Results 183

6.26 Jul 26, 2022: Hospital leaders explore the future of insulin management at Glytec’s Conference on Glycemic Innovation and Collaboration 184

6.27 Jul 26, 2022: Nitto Denko Consolidated Financial Statements for the First Quarter Ended June 30, 2022 185

6.28 Jul 24, 2022: Annapolis Financial Services Has $359,000 Stake in Johnson & Johnson 186

6.29 Jul 21, 2022: Roche: Appointed Thomas Schinecker as New CEO Effective March 15, 2023 186

6.30 Jul 21, 2022: Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement 186

6.31 Jul 20, 2022: Johnson & Johnson cuts sales forecasts 186

6.32 Jul 20, 2022: Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance 187

6.33 Jul 18, 2022: Johnson & Johnson’s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 187

6.34 Jul 12, 2022: Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3 2022 188

6.35 Jul 09, 2022: Modular Medical Announces Participation at Upcoming Investor Conferences 188

6.36 Jun 30, 2022: Annual General Meeting of Ypsomed elects new Chairman 189

6.37 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director 189

6.38 Jun 27, 2022: Ist Kalbe Farma (KLBF) Subsidiary IPO Plan Delayed 190

6.39 Jun 24, 2022: Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts 190

6.40 Jun 10, 2022: Midatech Pharma to appoint Dr. Stephen Parker as non-executive Chairman of the Board 190

6.41 Jun 09, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 190

6.42 Jun 07, 2022: BD Names Simon Campion as Medical Segment President 191

6.43 Jun 07, 2022: EEOC Sues Novo Nordisk for age discrimination 191

6.44 Jun 06, 2022: Retractable Technologies, announces reduction in Workforce 192

6.45 Jun 06, 2022: New study shows open-source automated insulin delivery is a safe and effective treatment option for people with type 1 diabetes 192

6.46 Jun 03, 2022: Lilly to Participate in Goldman Sachs Global Healthcare Conference 193

6.47 Jun 03, 2022: Eli Lilly announces its new president and general manager for Latam 193

6.48 Jun 02, 2022: Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference 194

6.49 Jun 02, 2022: BD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference 194

6.50 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results 194

6.51 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase 194

6.52 May 25, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 194

6.53 May 24, 2022: Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS) 194

6.54 May 24, 2022: Midatech Pharma Announces Notice of Annual General Meeting 195

6.55 May 20, 2022: Dr. Carol Swallow appointed Chair of the Department of Surgery at the University of Toronto 196

6.56 May 16, 2022: EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue 197

6.57 May 12, 2022: AstraZeneca joins Accumulus Synergy as a sponsor to accelerate the delivery of medicines to patients 198

6.58 May 12, 2022: Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference 198

6.59 May 11, 2022: Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company 198

6.60 May 11, 2022: Babson, BD expand strategic partnership to advance diagnostic blood collection in new care settings 199

6.61 May 10, 2022: Johnson & Johnson MedTech Adds New CFO to the Mix 200

6.62 May 10, 2022: Bayer Group Announced First quarter 2022 strong sales and earnings growth 200

6.63 May 09, 2022: Embecta to Participate in Upcoming Investor Conferences in May 202

6.64 May 06, 2022: Mary Lynne Hedley Elected to Lilly Board of Directors 202

6.65 May 05, 2022: Insulet Announces CEO Transition 203

6.66 May 05, 2022: Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year 204

6.67 May 05, 2022: MannKind Corporation Reports 2022 First Quarter Financial Results 205

6.68 May 04, 2022: Tandem Diabetes Care Announces First Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance 207

6.69 May 03, 2022: Sanofi: Annual General Meeting of May 3, 2022 209

6.70 May 03, 2022: Lilly to Participate in Bank of America Securities 2022 Healthcare Conference 209

6.71 May 03, 2022: Pfizer Reports First quarter 2022 Results 209

6.72 May 03, 2022: Receipt of Research & Development Tax Incentive 215

6.73 May 02, 2022: Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference 215

6.74 Apr 30, 2022: Shanghai Kindly Enterprise Development Group announce 2021 First Quarter Report 215

6.75 Apr 29, 2022: BD to Present at the BofA Securities 2022 Healthcare Conference 216

6.76 Apr 28, 2022: Integer Holdings Corporation Reports First Quarter 2022 Results 216

6.77 Apr 28, 2022: Biocon Announces Statement of Audited Standalone & Consolidated Financial Results for the Quarter And Year Ended March 31, 2022 218

6.78 Apr 27, 2022: Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer 219

6.79 Apr 26, 2022: Midatech Pharma Results for the Year Ended 31 December 2021 220

6.80 Apr 25, 2022: Shanghai Kindly Enterprise Development Group announce 2022 First Quarter Report 221

6.81 Apr 21, 2022: Bayer appoints Tara Frenkl as the new Head of Oncology Development at its Oncology Strategic Business Unit 222

6.82 Apr 20, 2022: Johnson & Johnson to Participate in the UBS Global Healthcare Conference 222

6.83 Apr 20, 2022: Shanghai Kindly Enterprise Development Group announce 2021 Annual Report 222

6.84 Apr 19, 2022: Johnson & Johnson Reports Q1 2022 Results 226

6.85 Apr 19, 2022: embecta Announces Second Quarter 2022 Earnings Conference Call Information 227

6.86 Apr 19, 2022: Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28 228

6.87 Apr 11, 2022: Kuleana Technology receives the NKF Innovation Fund’s first dialysis investment 228

6.88 Apr 07, 2022: Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022 229

6.89 Apr 07, 2022: Johnson & Johnson to Participate in the BofA Securities 2022 Healthcare Conference 229

6.90 Mar 31, 2022: Retractable Technologies Reports Results for 2021 229

6.91 Mar 30, 2022: ConvaTec Group announces Annual Report and Accounts 2021 and Notice of AGM 230

6.92 Mar 24, 2022: Novo Nordisk Announces Resolutions from the Annual General Meeting 230

6.93 Mar 24, 2022: Integer Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 232

6.94 Mar 24, 2022: Resolutions from the Annual General Meeting of Novo Nordisk 232

6.95 Mar 23, 2022: AstraZeneca Notice of AGM 233

6.96 Mar 21, 2022: BD provides update regarding the planned spinoff of Embecta 234

6.97 Mar 17, 2022: Integer Announces Board Leadership Transition 236

6.98 Mar 17, 2022: Integer to Take Part in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum 236

6.99 Mar 17, 2022: ConvaTec Group Announces Board Change 236

6.100 Mar 15, 2022: Johnson & Johnson to Host Investor Conference Call on First-Quarter Results 236

6.101 Mar 15, 2022: Opentrons Labworks Appoints Chief Financial Officer, and Chief Legal and Compliance Officer 237

6.102 Mar 10, 2022: EOFlow Announces Board Member Change to Sharpen its Focus on the US Market 238

6.103 Mar 08, 2022: ConvaTec Group Annual Results for the twelve months ended 31 December 2021 238

6.104 Mar 08, 2022: MannKind to Participate in Oppenheimer 32nd Annual Healthcare Conference 239

6.105 Mar 08, 2022: Stevanato Group Reports Record 2021 Revenue of €843.9 million 239

6.106 Mar 08, 2022: ConvaTec Group Announces Annual Results for the twelve months ended 31 December 2021 242

6.107 Feb 28, 2022: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 246

6.108 Feb 24, 2022: BD to Present at the Cowen 42nd Annual Health Care Conference 246

6.109 Feb 23, 2022: embecta to Host Virtual Investor Event Ahead of Planned Spinoff from BD 246

6.110 Feb 23, 2022: Ypsomed focuses on growth and strengthens its business units 246

6.111 Feb 23, 2022: Bd Appoints Shana Neal as Chief People Officer 247

6.112 Feb 21, 2022: MannKind Corp to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022 248

6.113 Feb 21, 2022: Notice for the Annual General Meeting of Novo Nordisk 248

6.114 Feb 18, 2022: Shanghai MicroPort Medical Group announces Chairman of the Board of Directors, Chairman of the Supervisory Committee, and Senior Management Announcement 249

6.115 Feb 16, 2022: Insulet to Present at Upcoming Investor Conferences 249

6.116 Feb 16, 2022: Raumedic appoints new CEO at its U.S. headquarters 249

6.117 Feb 15, 2022: Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors 250

6.118 Feb 10, 2022: AstraZeneca announces Full year and Q4 2021 results 250

6.119 Feb 09, 2022: Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference 252

6.120 Feb 09, 2022: Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 252

6.121 Feb 07, 2022: Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine 252

6.122 Feb 07, 2022: Johnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference 253

6.123 Feb 03, 2022: Roche reports good results in 2021 253

6.124 Feb 03, 2022: F. Hoffmann-La Roche Announces Financial Results for fiscal 2021 258

6.125 Feb 01, 2022: Pfizer Announces New Chief Development Officer 258

6.126 Jan 31, 2022: Poly Medicure Announces Unaudited Financial Results for the Quarter and Nine Month Ended December 31 2021 259

6.127 Jan 31, 2022: Poly Medicure Announces Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31 2021 260

6.128 Jan 27, 2022: Johnson & Johnson to Participate in Citi’s 2022 Virtual Healthcare Conference 260

6.129 Jan 27, 2022: ConvaTec Group Announce Board Committee Changes 261

6.130 Jan 25, 2022: Johnson & Johnson Reports Q4 and Full-Year 2021 Results 261

6.131 Jan 22, 2022: Eoflow participates in JP Morgan Healthcare Conference 262

6.132 Jan 20, 2022: Biocon Announces un-audited financial results for the quarter and nine months ended December 31, 2021 262

6.133 Jan 19, 2022: Brighter signs an agreement in the UK for clinical research with insulin-treated diabetes patients 262

6.134 Jan 18, 2022: Health2Sync expands product offering in chronic disease management with real word data integration and analytics 263

6.135 Jan 18, 2022: NuGen announces a $333,000, 5-year distribution agreement with Intermediq for its InsuJet needle-free injection device 264

6.136 Jan 18, 2022: Eoflow, ESG/Ethical Management Proclamation Ceremony held 265

6.137 Jan 14, 2022: Novo Nordisk announces settlement of securities lawsuit in Denmark 265

6.138 Jan 12, 2022: Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021 265

6.139 Jan 11, 2022: EOFlow to participate in the JP Morgan Healthcare Conference 266

6.140 Jan 10, 2022: Johnson & Johnson Medical Devices Companies: Reimagining the patient journey in a digital era 266

6.141 Jan 06, 2022: BD Announces Change to Virtual 2022 Annual Meeting of Shareholders 268

6.142 Jan 05, 2022: Nektar Therapeutics’ President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference 269

6.143 Jan 05, 2022: BD to announce financial results for its first quarter of fiscal year 2022 269

6.144 Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference 269

6.145 Jan 03, 2022: Mike Hu to join Gan & Lee Pharmaceuticals as Chief Executive Officer and President of Gan & Lee USA 269

6.146 Dec 30, 2021: Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 270

6.147 Dec 22, 2021: Eoflow, selected as one of the ‘National Innovative Companies 1000’ in the field of health and diagnosis 270

6.148 Dec 21, 2021: BD Announces Board of Directors for embecta, the Planned Spinoff of its Diabetes Care Business 271

6.149 Dec 14, 2021: Hindustan Syringes resumes production after brief pause 273

6.150 Dec 10, 2021: Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results 273

6.151 Dec 09, 2021: Convatec Announces Chief Financial Officer succession 274

6.152 Dec 08, 2021: Johnson & Johnson to Participate in the 40th Annual J.P. Morgan Healthcare Conference 275

6.153 Dec 08, 2021: Dr Jens von Lackum appointed to the Management Board of B. Braun SE 275

6.154 Dec 03, 2021: Roche Announces Changes in the Board of Directors 275

6.155 Dec 02, 2021: Tandem Diabetes Care Announces Expansion of Senior Leadership Team 276

6.156 Nov 27, 2021: Supporting the national healthcare industry’s security, Kalbe open opportunities for domestic production cooperation 276

6.157 Nov 26, 2021: Roche Notice Extraordinary General Meeting 2021 276

6.158 Nov 24, 2021: Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 277

6.159 Nov 18, 2021: Tandem Diabetes Care to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference 277

6.160 Nov 18, 2021: MicroPort RehabTech TherMotion Cryo-Thermo compression device approved for marketing in China 278

6.161 Nov 16, 2021: Retractable Technologies Reports $44.1 Million in Operating Income for the First Nine Months Of 2021 278

6.162 Nov 12, 2021: Government of Canada commemorates the discovery of insulin on 100th anniversary of this life-saving medical breakthrough 280

6.163 Nov 11, 2021: Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors 281

6.164 Nov 11, 2021: Targeting patients of cancer, thallasemia, HIV/AIDS and other autoimmune diseases Kalbe and Hermina Hospital held a Covid-19 vaccination center in Bandung 281

6.165 Nov 10, 2021: Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 282

6.166 Nov 10, 2021: Kalbe develops surgical suture product domestically produced 282

6.167 Nov 09, 2021: Rodrigo Santos Named Member of the Board of Management, Bayer AG, and President of the Crop Science Division 283

6.168 Nov 04, 2021: Tandem Diabetes Care Announces Third Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance 283

6.169 Nov 04, 2021: Bayer announces Christoph Koenen as new Global Head of Clinical Development and Operations within Pharmaceuticals Research and Development at Bayer 285

6.170 Nov 04, 2021: Antares Pharma Reports Third Quarter 2021 Financial and Operating Results 285

6.171 Nov 04, 2021: Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year 287

6.172 Nov 04, 2021: Nektar Therapeutics Reports Third Quarter 2021 Financial Results 288

6.173 Nov 04, 2021: Ypsomed is growing and expects a further increase 290

6.174 Nov 03, 2021: Novo Nordisk’s net profit increased by 12% in the first nine months of 2021 291

6.175 Nov 01, 2021: Poly Medicure announces Unaudited Financial Results Standalone & Consolidated for the Second quarter and half year ended on 30th September 2021 292

6.176 Oct 28, 2021: Sanofi announces strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER 292

6.177 Oct 28, 2021: Integer Holdings Reports Third Quarter 2021 Results 302

6.178 Oct 26, 2021: BD to Host Investor Day on November 12 303

6.179 Oct 24, 2021: Biocon Announces Financial Results For The Quarter And Half Year Ended September 30, 2021 304

6.180 Oct 20, 2021: F. Hoffmann-La Roche Announces Third Quarter Sales 2021 304

6.181 Oct 18, 2021: Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford 304

6.182 Oct 15, 2021: Kalbe holds Covid-19 vaccination center for patients of cancer, thallasemia, HIV/AIDS and other autoimmune diseases 305

6.183 Oct 15, 2021: Kalbe optimistic to achieve double-digit growth 305

6.184 Oct 12, 2021: Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021 306

6.185 Oct 12, 2021: Johnson & Johnson Announces Jessica Moore as Vice President of Investor Relations 307

6.186 Oct 11, 2021: Innovation Zed Announce Non-Invasive Continuous Glucose Monitoring Project and Appointment of a New Researcher 307

6.187 Oct 11, 2021: Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference 308

6.188 Oct 07, 2021: Tandem Diabetes Care to Announce Third Quarter 2021 Financial Results on November 3, 2021 308

6.189 Oct 07, 2021: Construction begins on 280,000-square-meter MicroPort MegaFactory and global medical experience center 309

6.190 Oct 05, 2021: Kalbe and Kompas Gramedia held the second-dose vaccination center for the people of Pekanbaru 310

6.191 Sep 30, 2021: Shanghai Kindly Enterprise Development Group announce 2021 Third Quarter Report 311

6.192 Sep 29, 2021: Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021 311

6.193 Sep 28, 2021: Integer Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 312

6.194 Sep 27, 2021: AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases 27 September 2021 312

6.195 Sep 26, 2021: USFDA issues six observations after inspection of Biocon’s Malaysian arm manufacturing facility 313

6.196 Sep 21, 2021: AstraZeneca to invest $360m in advanced manufacturing facility in Ireland 313

6.197 Sep 20, 2021: Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 314

7 Appendix 315

7.1 Methodology 315

7.2 About GlobalData 318

7.3 Contact Us 318

7.4 Disclaimer 318

List of Tables

Insulin Delivery – Pipeline Products by Stage of Development 21

Insulin Delivery – Pipeline Products by Segment 22

Insulin Delivery – Pipeline Products by Territory 23

Insulin Delivery – Pipeline Products by Regulatory Path 24

Insulin Delivery – Pipeline Products by Estimated Approval Date 25

Insulin Delivery – Ongoing Clinical Trials 26

Insulin Delivery Companies – Pipeline Products by Stage of Development 27

Insulin Delivery – Pipeline Products by Stage of Development 30

Abbott Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview 33

Freestyle Libre Connected Insulin Pen – Product Status 33

Freestyle Libre Connected Insulin Pen – Product Description 33

Aerami Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Dance-501 – Product Status 34

Dance-501 – Product Description 34

American Chemical Society Pipeline Products & Ongoing Clinical Trials Overview 35

Mucoadhesive Insulin Patch – Product Status 35

Mucoadhesive Insulin Patch – Product Description 35

AMF Medical SA Pipeline Products & Ongoing Clinical Trials Overview 36

Sigi Insulin Management System – Product Status 36

Sigi Insulin Management System – Product Description 36

Amrita Vishwa Vidyapeetham Pipeline Products & Ongoing Clinical Trials Overview 37

Amrita Insulin Pump – Product Status 37

Amrita Insulin Pump – Product Description 37

Andain, Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Gaia Med Diamond Semi-Disposable Pump – Product Status 38

Gaia Med Diamond Semi-Disposable Pump – Product Description 38

Gemini Pump – Product Status 39

Gemini Pump – Product Description 39

Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 40

Hypoglycemia-Hyperglycemia Minimizer System – Product Status 40

Hypoglycemia-Hyperglycemia Minimizer System – Product Description 40

ASTI Corp Pipeline Products & Ongoing Clinical Trials Overview 41

Plastic Microneedle System – Product Status 41

Plastic Microneedle System – Product Description 41

Avecho Biotechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview 42

TPM-Insulin Patch – Product Status 42

TPM-Insulin Patch – Product Description 42

Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 43

Extended Wear Insulin Infusion Set – Product Status 43

Extended Wear Insulin Infusion Set – Product Description 43

Type 2 Patch Pump – Product Status 44

Type 2 Patch Pump – Product Description 44

Bigfoot Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Bigfoot Certainty – Product Status 45

Bigfoot Certainty – Product Description 45

Biocon Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

Semglee Prefilled Pen – Product Status 46

Semglee Prefilled Pen – Product Description 46

Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 47

KiCoPen – Product Status 47

KiCoPen – Product Description 47

Cellnovo Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 48

Wireless Insulin Pump System Integrated With inControl AP – Product Status 48

Wireless Insulin Pump System Integrated With inControl AP – Product Description 48

Companion Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 49

Smart Insulin Pen – Advanced Decision Support – Product Status 49

Smart Insulin Pen – Advanced Decision Support – Product Description 49

ConvaTec Group Plc Pipeline Products & Ongoing Clinical Trials Overview 50

Infusion Set – Tandem Mobi – Product Status 50

Infusion Set – Tandem Mobi – Product Description 50

Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 51

JewelPump – Product Status 51

JewelPump – Product Description 51

JewelPUMP2 – Product Status 52

JewelPUMP2 – Product Description 52

Defymed SAS Pipeline Products & Ongoing Clinical Trials Overview 53

ExOlin – Product Status 53

ExOlin – Product Description 53

Defymed SAS – Ongoing Clinical Trials Overview 54

ExOlin – An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia 55

Dermisonics Inc Pipeline Products & Ongoing Clinical Trials Overview 56

U-Strip – Product Status 56

U-Strip – Product Description 56

Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview 57

AID System – Product Status 57

AID System – Product Description 58

AIR Insulin System – Product Status 58

AIR Insulin System – Product Description 58

BASAGLAR Tempo Pen – Product Status 59

BASAGLAR Tempo Pen – Product Description 59

Connected Care Pre-Filled Insulin Pen – Product Status 59

Connected Care Pre-Filled Insulin Pen – Product Description 60

Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 61

ESYSTA BT Pen – Product Status 61

ESYSTA BT Pen – Product Description 61

EOFlow Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

EOPancreas System – Product Status 62

EOPancreas System – Product Description 62

EOPatch Wearable Insulin Pump System – Product Status 63

EOPatch Wearable Insulin Pump System – Product Description 63

Erech Finance Cahalacha Ltd Pipeline Products & Ongoing Clinical Trials Overview 64

Long Acting Insulin Therapy Device – Product Status 64

Long Acting Insulin Therapy Device – Product Description 64

Hospira Inc Pipeline Products & Ongoing Clinical Trials Overview 65

Integrated Symbiq/EndoTool System – Product Status 65

Integrated Symbiq/EndoTool System – Product Description 65

Imagine Medical Device Inc. Pipeline Products & Ongoing Clinical Trials Overview 66

Insulin Syringe – Product Status 66

Insulin Syringe – Product Description 66

InsuLenz Pipeline Products & Ongoing Clinical Trials Overview 67

Smart Polymer Contact Lens – Product Status 67

Smart Polymer Contact Lens – Product Description 67

Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 68

Omnipod 5 – Product Status 68

Omnipod 5 – Product Description 69

Omnipod DASH Insulin Management System – Product Status 69

Omnipod DASH Insulin Management System – Product Description 69

Omnipod U-200 Insulin Management System – Product Status 70

Omnipod U-200 Insulin Management System – Product Description 70

Omnipod U-500 Insulin Management System – Product Status 70

Omnipod U-500 Insulin Management System – Product Description 71

Insulet Corp – Ongoing Clinical Trials Overview 72

Omnipod 5 – Automated Insulin Delivery for Inpatients with DysGlycemia (AIDING) Feasibility Study 73

Omnipod 5 – Efficacy and Safety of the Omnipod 5 System Compared to Pump Therapy in the Treatment of Type 1 Diabetes: A Randomized, Parallel-Group Clinical Trial 73

Omnipod 5 – Evaluating the Safety and Effectiveness of the Omnipod 5 Automated Insulin Delivery System in Patients with Type 2 Diabetes 73

Omnipod 5 – Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes 74

Omnipod DASH Insulin Management System – Evaluation of the Usability and Effect on the Metabolic Control of the Omnipod DASH Insulin Administration System in Children and Adolescents With Type 1 Diabetes Mellitus 75

Iowa State University Pipeline Products & Ongoing Clinical Trials Overview 76

Feed Forward Insulin Delivery System – Product Status 76

Feed Forward Insulin Delivery System – Product Description 76

Kailian Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 77

InnoPen Electric Insulin Pen – Product Status 77

InnoPen Electric Insulin Pen – Product Description 77

InnoTouch Insulin Application Pump – Product Status 78

InnoTouch Insulin Application Pump – Product Description 78

Le Pump Insulin Pump II – Product Status 78

Le Pump Insulin Pump II – Product Description 79

Lenomed ATA-I-1-0 Insulin Pump – Product Status 79

Lenomed ATA-I-1-0 Insulin Pump – Product Description 79

LifeScan Inc Pipeline Products & Ongoing Clinical Trials Overview 80

ONETOUCH Ping Verio Insulin Pump With Meter Remote – Product Status 80

ONETOUCH Ping Verio Insulin Pump With Meter Remote – Product Description 80

MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview 81

AFREZZA – Medtone Inhaler – Product Status 81

AFREZZA – Medtone Inhaler – Product Description 82

Afrezza – Pediatric Use – Product Status 82

Afrezza – Pediatric Use – Product Description 82

Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 83

Med-Jet MIT-P-I – Product Status 83

Med-Jet MIT-P-I – Product Description 83

Medicsensors SL Pipeline Products & Ongoing Clinical Trials Overview 84

Insulin Smartpatch – Product Status 84

Insulin Smartpatch – Product Description 84

MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 85

Insulin Guard Self-Injector Safety Needle – Product Status 85

Insulin Guard Self-Injector Safety Needle – Product Description 85

MedSolve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 86

Freehand Patch Pump – Product Status 86

Freehand Patch Pump – Product Description 86

Medtronic MiniMed Inc Pipeline Products & Ongoing Clinical Trials Overview 87

Insulin Delivery System – Product Status 87

Insulin Delivery System – Product Description 87

Minimed 780G – Adults – Product Status 88

Minimed 780G – Adults – Product Description 88

Minimed 780G – Pediatric – Product Status 88

Minimed 780G – Pediatric – Product Description 89

MiniMed Mio Advance Infusion Set – Product Status 89

MiniMed Mio Advance Infusion Set – Product Description 89

Medtronic MiniMed Inc – Ongoing Clinical Trials Overview 90

Minimed 780G – Adults – Advanced Hybrid Closed Loop Study in Adult Population with Type 1 Diabetes 92

Minimed 780G – Adults – Advanced Hybrid Closed-Loop Treatment in Adults with Type 1 Diabetes Not Meeting Glycaemic Targets: A Randomized Controlled Trial – The Steno 780G Study 92

Minimed 780G – Adults – Closed-loop Insulin Delivery in Pregnant Women with Type 1 Diabetes: A Randomized Controlled Trial: The CRISTAL Study 92

Minimed 780G – Adults – Effect of Automated Insulin Delivery with Advanced Closed-loop on Glucose Outcomes and Early-stage Diabetic Complications 93

Minimed 780G – Adults – Evaluation of the MiniMed 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp (Insulin Aspart Injection) 93

Minimed 780G – Adults – Evaluation of Two Levels of Health Care Interactions in Adolescents with Type 1 Diabetes on Advanced Hybrid Closed Loop System MiniMed 780G/ Zeus Sensor 93

Minimed 780G – Adults – Feasibility Study for a Medtronic next Generation Hybrid Closed Loop System in Adults with Type 1 Diabetes 94

Minimed 780G – Adults – In-Home Study With MiniMed 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes 94

Minimed 780G – Adults – Optimising Glycaemia Around Dynamic Physical Exercise with Advanced Hybrid-closed-loop Therapy Use in Type 1 Diabetes: ‘The SMART Study’ 94

Minimed 780G – Adults – Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects 95

Minimed 780G – Adults – Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev Insulin Lispro-aabc 95

Minimed 780G – Adults – The MiniMed 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects with Type 1 Diabetes in France: EQOL Study 95

Minimed 780G – Adults – Transition of Patients with T1D From Multiple Daily Injection (MDI) and Self-monitoring of Blood Glucose (SMBG) Directly to MiniMed 780G Advanced Hybrid Closed Loop (AHCL) System :Impact on Glucose Control and Quality of Life Measures 96

Minimed 780G – Pediatric – Assessment of the Efficacy of Closed Loop Technology for Glucose Control in Young Children with Type 1 Diabetes 97

Minimed 780G – Pediatric – Assessment of the Feasibility of Using Closed Loop Technology in Young Children with Type 1 Diabetes Aged 2-7 97

Minimed 780G – Pediatric – Evaluation of the MiniMed 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp (Insulin Aspart Injection) 97

Minimed 780G – Pediatric – Evaluation of Two Levels of Health Care Interactions in Adolescents with Type 1 Diabetes on Advanced Hybrid Closed Loop System MiniMed 780G/ Zeus Sensor 98

Minimed 780G – Pediatric – Glycemic Outcomes and Safety with Minimed 780G System in Children with Type 1 Diabetes Aged 2-6 Years 98

Minimed 780G – Pediatric – Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev Insulin Lispro-aabc 98

Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 99

Implantable Insulin Pump – Product Status 99

Implantable Insulin Pump – Product Description 99

MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 100

Angel Touch – Product Status 100

Angel Touch – Product Description 100

La Fenice Pen – Product Status 101

La Fenice Pen – Product Description 101

La Fenice V – Product Status 101

La Fenice V – Product Description 101

MicroTech Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 102

Equil Insulin Pump – Child and Adolescent Use – Product Status 102

Equil Insulin Pump – Child and Adolescent Use – Product Description 102

Second-Generation Patch Insulin Pump System – Product Status 103

Second-Generation Patch Insulin Pump System – Product Description 103

Modular Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 104

MODD1 (MODD Pivot) – Product Status 104

MODD1 (MODD Pivot) – Product Description 104

MODD1+ – Product Status 105

MODD1+ – Product Description 105

NanoDerma Ltd Pipeline Products & Ongoing Clinical Trials Overview 106

Intranasal Insulin Delivery Device – Product Status 106

Intranasal Insulin Delivery Device – Product Description 106

nGageIT Digital Health Inc Pipeline Products & Ongoing Clinical Trials Overview 107

InsuloSenz – Product Status 107

InsuloSenz – Product Description 107

Nitto Denko Corp Pipeline Products & Ongoing Clinical Trials Overview 108

PassPort Transdermal Basal Insulin Patch – 12 Hours – Product Status 108

PassPort Transdermal Basal Insulin Patch – 12 Hours – Product Description 108

PassPort Transdermal Basal Insulin Patch – 24Hours – Product Status 109

PassPort Transdermal Basal Insulin Patch – 24Hours – Product Description 109

North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 110

Pulsatile Noninvasive Drug Delivery System – Product Status 110

Pulsatile Noninvasive Drug Delivery System – Product Description 110

Novo Nordisk AS Pipeline Products & Ongoing Clinical Trials Overview 111

AERx iDMS – Product Status 111

AERx iDMS – Product Description 112

Ingestible SOMA – Product Status 112

Ingestible SOMA – Product Description 112

LUMI Device – Product Status 113

LUMI Device – Product Description 113

NuGen Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 114

InsuJet – Product Status 114

InsuJet – Product Description 114

Pennsylvania State University Pipeline Products & Ongoing Clinical Trials Overview 115

Nanobot Based Insulin Pumping Device – Product Status 115

Nanobot Based Insulin Pumping Device – Product Description 115

Perikinetics Inc Pipeline Products & Ongoing Clinical Trials Overview 116

PK Insulin Delivery Conduit – Product Status 116

PK Insulin Delivery Conduit – Product Description 116

Phluid Corporation Pipeline Products & Ongoing Clinical Trials Overview 117

Ambulatory Diabetes Pump – Product Status 117

Ambulatory Diabetes Pump – Product Description 117

PhysioLogic Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 118

ThinPump – Product Status 118

ThinPump – Product Description 118

PositiveID Corp Pipeline Products & Ongoing Clinical Trials Overview 119

Insulin Tracker – Product Status 119

Insulin Tracker – Product Description 119

Prometheon Pharma LLC Pipeline Products & Ongoing Clinical Trials Overview 120

TruePatch – Basal Insulin – Product Status 120

TruePatch – Basal Insulin – Product Description 120

TruePatch – Rapid-Acting (Bolus) Insulin – Product Status 121

TruePatch – Rapid-Acting (Bolus) Insulin – Product Description 121

Qlibrium Inc Pipeline Products & Ongoing Clinical Trials Overview 122

QForma – Product Status 122

QForma – Product Description 122

Sanofi Pipeline Products & Ongoing Clinical Trials Overview 123

Fix-Flex Device – Product Status 123

Fix-Flex Device – Product Description 123

SFC Fluidics LLC Pipeline Products & Ongoing Clinical Trials Overview 124

Dual ePump – Product Status 124

Dual ePump – Product Description 124

Open-Protocol Patch Pump System – Product Status 125

Open-Protocol Patch Pump System – Product Description 125

PANDA – Product Status 125

PANDA – Product Description 126

Pod Automated Insulin Delivery Device – Product Status 126

Pod Automated Insulin Delivery Device – Product Description 126

Sooil Development Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 127

Dana-I Pump – Product Status 127

Dana-I Pump – Product Description 127

Spring Health Solutions Ltd. Pipeline Products & Ongoing Clinical Trials Overview 128

Spring Zone Hybrid Patch Pump – Product Status 128

Spring Zone Hybrid Patch Pump – Product Description 128

Tandem Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview 129

CSII Catheter – Product Status 129

CSII Catheter – Product Description 129

SteadiSet Infusion Set – Product Status 130

SteadiSet Infusion Set – Product Description 130

t:slim X3 Insulin Pump – Product Status 130

t:slim X3 Insulin Pump – Product Description 131

Tandem Mobi – Product Status 131

Tandem Mobi – Product Description 131

Tandem Mobi: Tubeless – Product Status 132

Tandem Mobi: Tubeless – Product Description 132

Tandem Patch – Product Status 132

Tandem Patch – Product Description 133

Tandem Diabetes Care Inc – Ongoing Clinical Trials Overview 134

CSII Catheter – A Pilot Study for the Systematic Evaluation of the Inflammatory Response to Commercially Available Insulin Infusion Catheters in Subcutaneous Adipose Tissue 135

SteadiSet Infusion Set – A Pivotal, Non-randomized, Prospective and Single Arm Study to Evaluate SteadiFlow Seven-day-wear Infusion Set Technology in Type I Diabetes Subjects 136

TempraMed Israel Ltd Pipeline Products & Ongoing Clinical Trials Overview 137

VIVI Cap Smart – Product Status 137

VIVI Cap Smart – Product Description 137

Thermalin Inc Pipeline Products & Ongoing Clinical Trials Overview 138

Insulin Patch – Product Status 138

Insulin Patch – Product Description 138

Stabilized and Ultra-Rapid Insulin Pump – Product Status 139

Stabilized and Ultra-Rapid Insulin Pump – Product Description 139

StampPump – Product Status 139

StampPump – Product Description 140

Ultra-Rapid Highly-Concentrated Insulin Pump – Product Status 140

Ultra-Rapid Highly-Concentrated Insulin Pump – Product Description 140

Transdermal Specialties Inc Pipeline Products & Ongoing Clinical Trials Overview 141

U-Strip Insulin Patch – Product Status 141

U-Strip Insulin Patch – Product Description 141

Triple Jump Israel Ltd Pipeline Products & Ongoing Clinical Trials Overview 142

Insulin Patch Pump – Product Status 142

Insulin Patch Pump – Product Description 142

University of KwaZulu-Natal Pipeline Products & Ongoing Clinical Trials Overview 143

Pectin Insulin Gel Skin Patch – Product Status 143

Pectin Insulin Gel Skin Patch – Product Description 143

University of Limerick Pipeline Products & Ongoing Clinical Trials Overview 144

Smart Gluco – Product Status 144

Smart Gluco – Product Description 144

University of Massachusetts Amherst Pipeline Products & Ongoing Clinical Trials Overview 145

Insulin Delivery System – Product Status 145

Insulin Delivery System – Product Description 145

University of Missouri-Kansas City Pipeline Products & Ongoing Clinical Trials Overview 146

Light Activated Insulin Depot – Product Status 146

Light Activated Insulin Depot – Product Description 146

University of North Carolina Pipeline Products & Ongoing Clinical Trials Overview 147

Smart Cell Patch – Product Status 147

Smart Cell Patch – Product Description 147

Smart Insulin Patch – Product Status 148

Smart Insulin Patch – Product Description 148

University of Toronto Pipeline Products & Ongoing Clinical Trials Overview 149

Implantable Closed-Loop Insulin Delivery Device – Product Status 149

Implantable Closed-Loop Insulin Delivery Device – Product Description 149

Univlabs Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 150

Wearable Insulin Patch Pump – Product Status 150

Wearable Insulin Patch Pump – Product Description 150

Unomedical a/s Pipeline Products & Ongoing Clinical Trials Overview 151

Medtronic Extended Infusion Set – Product Status 151

Medtronic Extended Infusion Set – Product Description 151

Valeritas Inc Pipeline Products & Ongoing Clinical Trials Overview 152

V-Go Prefill Device – Product Status 152

V-Go Prefill Device – Product Description 152

V-Go SIM – Product Status 153

V-Go SIM – Product Description 153

ViCentra BV Pipeline Products & Ongoing Clinical Trials Overview 154

Kaleido Insulin Pump – Product Status 154

Kaleido Insulin Pump – Product Description 154

Kaleido Insulin Pump – Children And Adolescent – Product Status 155

Kaleido Insulin Pump – Children And Adolescent – Product Description 155

Vigmed Holding AB Pipeline Products & Ongoing Clinical Trials Overview 156

Insulin Needle – Product Status 156

Insulin Needle – Product Description 156

Washington University School of Medicine Pipeline Products & Ongoing Clinical Trials Overview 157

NICE Device – Product Status 157

NICE Device – Product Description 157

Ypsomed Holding AG Pipeline Products & Ongoing Clinical Trials Overview 158

Integrated Automated Insulin Delivery (AID) System – Product Status 158

Integrated Automated Insulin Delivery (AID) System – Product Description 159

Lanzi – Product Status 159

Lanzi – Product Description 159

Mylife Dose – Product Status 160

Mylife Dose – Product Description 160

mylife YpsoPod Insulin Pump – Tubeless – Product Status 160

mylife YpsoPod Insulin Pump – Tubeless – Product Description 161

mylife YpsoPump – Product Status 161

mylife YpsoPump – Product Description 161

Ypsomed Holding AG – Ongoing Clinical Trials Overview 162

mylife YpsoPump – Feasibility of Automated Insulin Delivery with an Interoperable Algorithm Using an Alternative Insulin Pump 163

mylife YpsoPump – First in Human Feasibility Study; Automated Insulin Delivery Utilizing the Dexcom Next Generation Algorithm in Adults with Type 1 Diabetes 163

Zealand Pharma AS Pipeline Products & Ongoing Clinical Trials Overview 164

HyoPen – Product Status 164

HyoPen – Product Description 164

HypoPal Rescue Pen – Product Status 165

HypoPal Rescue Pen – Product Description 165

V-Go Wearable Insulin Delivery Device – Product Status 165

V-Go Wearable Insulin Delivery Device – Product Description 166

Zealand Pharma AS – Ongoing Clinical Trials Overview 167

HyoPen – Ready-to-use Dasiglucagon for the Treatment of Postprandial Hypoglycaemia in Roux-en-Y Gastric Bypass Operated Patients 168

Zenomics Inc Pipeline Products & Ongoing Clinical Trials Overview 169

Smart Insulin Patch – Product Status 169

Smart Insulin Patch – Product Description 169

Glossary 317

List of Figures

Insulin Delivery – Pipeline Products by Stage of Development 21

Insulin Delivery – Pipeline Products by Segment 22

Insulin Delivery – Pipeline Products by Territory 23

Insulin Delivery – Pipeline Products by Regulatory Path 24

Insulin Delivery – Pipeline Products by Estimated Approval Date 25

Insulin Delivery – Ongoing Clinical Trials 26

Frequently Asked Questions

The US, Europe, China, Israel, South Korea, Canada, Australia, India, the UAE, and Hong Kong have products in the pipeline.

Some of the key segments in the Insulin delivery pipeline products market are Insulin Pumps, Patch Pumps, Insulin Pens, Reusable Insulin Pens, Disposable Insulin Pens, Disposable Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, and Programmable Insulin Patch Pumps – Pods.

The key regulatory paths followed by the Insulin delivery pipeline products market are 510(k), CE, NMPA, PMA, MDITAC, MDL, TGA, ICAC, MDCO, and Ninsho.

The key companies in the Insulin delivery pipeline products market are Abbott Diabetes Care Inc, Aerami Therapeutics Inc, American Chemical Society, AMF Medical SA, Amrita Vishwa Vidyapeetham, Andain, Inc, Animas Corp, ASTI Corp, Avecho Biotechnology Ltd, and Becton Dickinson and Co.

$4000

Can be used by individual purchaser only

$12000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.